Pfizer expands oncology and obesity pipelines as Coca-Cola extends dividend streak
Pfizer is leveraging recent acquisitions to build a new pipeline of blockbuster drugs to sustain its high dividend yield, while Coca-Cola continues its decades-long record of shareholder returns.
Pfizer is restructuring its pharmaceutical pipeline to offset post-pandemic revenue declines and sustain a forward-looking dividend yield of 6.9 percent. The drugmaker is relying on its historical ability to replace expiring patents to fund future shareholder returns. Meanwhile, Coca-Cola continues to reward investors through its 64-year streak of annual dividend increases.
The company acquired Seagen in 2023 to bolster its oncology portfolio and drive future growth. This strategic expansion includes the cancer treatment Padcev, which recently gained regulatory approval for muscle-invasive bladder cancer when combined with Merck’s Keytruda. Management expects these targeted efforts to yield at least eight new blockbuster drugs generating over $1 billion in annual revenue by 2030.
Pfizer is simultaneously entering the highly competitive weight-loss sector following its late-2025 acquisition of Metsera. The transaction secures MET-097i, a GLP-1 treatment positioned to compete directly with Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy through its monthly dosing regimen. This convenience factor could capture significant market share in an obesity drug sector projected to reach $133 billion annually by 2031, according to Mordor Intelligence.
Navigating severe patent cliffs is familiar territory for the pharmaceutical giant. The business previously overcame the expiration of major intellectual property protections for Lipitor, Lyrica, and Viagra by successfully developing subsequent revenue drivers. Market participants are now evaluating whether the new oncology and obesity assets can replicate that historical operational resilience.
In contrast to Pfizer’s transitional pipeline phase, Coca-Cola represents established income stability for institutional portfolios. The beverage corporation has paid a quarterly dividend for decades without any interruption. Its consistent ability to raise the per-share payment every year for the past 64 years underscores a mature business model heavily focused on reliable capital returns.
For income-focused investors, these two equities illustrate contrasting approaches to long-term capital allocation and risk management. Pfizer offers a high current yield backed by aggressive pipeline expansion and strategic acquisitions. Conversely, Coca-Cola provides predictable growth through an unmatched history of dividend hikes, highlighting the diverse strategies available in the current market environment.
